Metabolic changes caused by first generation antipsychotic versus second generation antipsychotic in schizophrenic patients

Freedman, 2003, Schizophrenia, N Engl J Med, 349, 1738, 10.1056/NEJMra035458 Henderson, 2000, Clozapine, diabetes mellitus, weight gain, and lipid abnormalities: a five-year naturalistic study, Am J Psychiatry, 157, 975, 10.1176/appi.ajp.157.6.975 Allison, 1999, Antipsychotic-induced weight gain: a comprehensive research synthesis, Am J Psychiatry, 156, 1686, 10.1176/ajp.156.11.1686 Newcomer, 2004, Abnormalities of glucose metabolism associated with atypical antipsychotic drugs, J Clin Psychiatry, 65, 36 Henderson, 2005, Glucose metabolism in patients with schizophrenia treated with atypical antipsychotic agents: a frequently sampled intravenous glucose tolerance test and minimal model analysis, Arch Gen Psychiatry, 62, 19, 10.1001/archpsyc.62.1.19 Wu, 2006, Effects of typical and atypical antipsychotics on glucose-insulin homeostasis and lipid metabolism in first-episode schizophrenia, Psychopharmacology (Berl), 186, 572, 10.1007/s00213-006-0384-5 Newcomer, 2002, Abnormalities in glucose regulation during antipsychotic treatment of schizophrenia, Arch Gen Psychiatry, 59, 337, 10.1001/archpsyc.59.4.337 Kouvak-Mufic, 2007, Metabolic side-effects of novel antipsychotic drugs, Biochemia Med, 17, 178, 10.11613/BM.2007.016 Bhana, 2001, Olanzapine: an updated review of its use in the management of schizophrenia, Drugs, 61, 111, 10.2165/00003495-200161010-00011 Bennett, 2003, Psychotropic drugs, 367 Kaushal, 2012, Comparison of fasting blood sugar and serum lipid profile changes after treatment with atypical antipsychotics olanzapine and risperidone, Singapore Med J, 53, 488 Haupt, 2001, Hyperglycemia and antipsychotic medications, J Clin Psychiatry, 62, 15 Melkerrson, 2000, Elevated levels of insulin, leptin, and blood lipids in olanzapine-treated patients with schizophrenia or related psychoses, J Clin Psychiatry, 61, 742, 10.4088/JCP.v61n1006 Koro, 2002, An assessment of the independent effects of olanzapine and risperidone exposure on the risk of hyperlipidemia in schizophrenic patients, Arch Gen Psychiatry, 59, 1021, 10.1001/archpsyc.59.11.1021 Meyer, 2002, A retrospective comparison of weight, lipid and glucose changes between risperidone and olanzapine treated inpatients: metabolic outcomes after 1 year, J Clin Psychiatry, 63, 425, 10.4088/JCP.v63n0509 Shirzadi, 2006, Side effects of atypical antipsychotics: extrapyramidal symptoms and the metabolic syndrome, Harv Rev Psychiatry, 14, 152, 10.1080/10673220600748486 Dimelis, 2002, Olanzapine vs. risperidone: impact on weight gain and blood lipids: is there any relationship with antipsychotic efficacy?, Eur Neuropsychopharmacol, 12, S328, 10.1016/S0924-977X(02)80501-6 Ishigooka, 2001, Efficacy and safety of olanzapine, an atypical antipsychotic, in patients with schizophrenia: results of open-label multicenter study in Japan, Psychiatry Clin Neurosci, 55, 353, 10.1046/j.1440-1819.2001.00875.x Simpson, 2002, Ziprasidone vs olanzapine in schizophrenia: 6-month continuation study, Eur Neuropsychopharmacol, 12, S311, 10.1016/S0924-977X(02)80460-6 Nemeroff, 1997, Dosing the antipsychotic medication olanzapine, J Clin Psychiatry, 58, 45 Meyer, 2001, Effects of atypical antipsychotics on weight and serum lipid levels, J Clin Psychiatry, 62, 27 Haddad, 2005, Weight change with atypical antipsychotics in the treatment of schizophrenia, J Psychopharmacol, 19, 16, 10.1177/0269881105058378